Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

BACKGROUND: Genetic variations of some driver genes in non-small cell lung cancer (NSCLC) had shown potential impact on immune microenvironment and associated with response or resistance to programmed cell death protein 1 (PD-1) blockade immunotherapy. We therefore undertook an exploratory analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Xue, Wu, De-Hua, Ma, Si-Cong, Wang, Jian, Tang, Xin-Ran, Kang, Shuai, Fu, Qiang John, Cao, Chuan-Hui, Luo, He-San, Chen, Yu-Han, Zhu, Hong-Bo, Yan, Hong-Hong, Wu, Yi-Long, Dong, Zhong-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328897/
https://www.ncbi.nlm.nih.gov/pubmed/32606052
http://dx.doi.org/10.1136/jitc-2019-000381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7328897/
https://www.ncbi.nlm.nih.gov/pubmed/32606052
http://dx.doi.org/10.1136/jitc-2019-000381

Ejemplares similares